BCAB Financials

Income Statement
MetricQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025
Revenue
6.5M
0
-100.0%
2.0M
0
0
Cost of Revenue
0
0
0
0
0
Gross Profit
6.5M
0
-100.0%
2.0M
0
0
Operating Expenses
6.3M
-32.6%
9.3M
-17.3%
11.3M
-18.4%
13.8M
-26.1%
18.6M
R&D
3.3M
-27.1%
4.6M
-42.7%
8.0M
-16.2%
9.5M
-30.3%
13.7M
SG&A
2.9M
-38.0%
4.7M
+45.0%
3.3M
-23.3%
4.3M
-14.4%
5.0M
Operating Income
227.0K
+102.4%
-9308000
-0.6%
-9255000
+32.9%
-13789000
+26.1%
-18647000
EBITDA
227.0K
+102.5%
-9188000
+0.5%
-9236000
+32.7%
-13733000
+25.9%
-18532000
Net Income
452.0K
+107.1%
-6344000
+35.2%
-9784000
+38.0%
-15778000
+15.7%
-18711000
EPS (Basic)
$0.27
+106.4%
$-4.22
-50.2%
$-2.81
+79.2%
$-13.50
+15.6%
$-15.99
EPS (Diluted)
$0.27
+106.4%
$-4.22
-50.2%
$-2.81
+79.2%
$-13.50
+15.6%
$-15.99
Shares (Diluted)
1.7M
+10.7%
1.5M
-56.9%
3.5M
+196.6%
1.2M
+0.4%
1.2M
BioAtla (BCAB) โ€” Financials